Mallinckrodt Acquires Questcor, to Join S&P 500 As Well - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:30PM CDT
Mallinckrodt announced the completion of its acquisition of Questcor Pharmaceuticals, Inc. in a deal valued at approximately $5.8 billion.
Supernus's SPN-810 Gets Fast Track Status for ADHD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 12:30PM CDT
Supernus Pharmaceuticals, Inc.'s (SUPN) attention deficit hyperactivity disorder (ADHD) candidate, SPN-810 has received Fast track status in the U.S.
Stock Futures Steer Higher; Dollar General, Akorn Rising
at Investor's Business Daily - Mon Aug 18, 8:04AM CDT
Stock futures were up and holding near early highs ahead of Monday's open, boosted by rallying European markets. Dow futures traded ahead 87.1 points. Nasdaq 100 futures were 20.3 points above fair market value. S&P 500 futures rose 10.7 points, and...
Akorn Has Returned 47.5% Since SmarTrend Recommendation (AKRX)
Comtex SmarTrend(R) - Fri Aug 15, 9:40AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 4 months, Akorn has returned 47.54% as of today's recent price of $36.22.
Perrigo Beats on Q4 Earnings and Sales, Provides Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 12:29PM CDT
Perrigo (PRGO) reported higher than expected earnings and revenues in the fourth quarter.
Akorn,Dean Foods, IMAX, Walt DisneyandLions Gate Entertainmenthighlighted as Zacks Bull and Bear of the Day
PR Newswire - Thu Aug 14, 8:30AM CDT
Zacks Equity Research highlights Akorn Inc (Nasdaq:AKRX-Free Report) as the Bull of the Day and Dean Foods Corp (NYSE
Cerulean Pharma (CERU) Worth Watching: Stock Soars 30.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 8:25AM CDT
Cerulean Pharma (CERU) was a big mover last session, with shares surging nearly 31% on the day.
Mallinckrodt Beats on Q3 Earnings and Revenues, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 13, 12:23PM CDT
Shares of Mallinckrodt plc (MNK) gained 0.46% following the company's third quarter fiscal 2014 (ended Jun 27, 2014) earnings report last week.
SmarTrend Watching for Potential Pullback in Shares of Akorn After 1.63% Gain
Comtex SmarTrend(R) - Tue Aug 12, 4:48PM CDT
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $34.57 to a high of $35.62. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $35.39 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Akorn Completes Acquisition of VersaPharm
GlobeNewswire - Tue Aug 12, 8:02AM CDT
Akorn, Inc. (Nasdaq:AKRX), a niche pharmaceutical company, announced today that it has completed its previously announced acquisition of VPI Holdings Corp., the parent company of VersaPharm Incorporated, for $440 million.
Relypsa (RLYP) Worth Watching: Stock Gains 13.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:46AM CDT
Relypsa (RLYP) was a big mover last session, with shares rising over 13% on the day.
Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Why Akorn (AKRX) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 11, 7:34AM CDT
Akorn’s small price movement but large earnings estimate revisions make it an unappreciated stock that might have potential for gains
Akorn: the Pharmaceutical Stock You Can’t Afford to Ignore
at The Street - Fri Aug 08, 11:18AM CDT
You may have never heard of Akorn, but investors in this pharmaceutical company have been richly rewarded in recent years.
Shares of AKRX Up 37.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 08, 9:14AM CDT
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on April 22nd, 2014 at $24.55. In approximately 4 months, Akorn has returned 37.39% as of today's recent price of $33.73.
Akorn Trading Goes Wild On Q2 Report, Finds Support
at Investor's Business Daily - Thu Aug 07, 5:02PM CDT
Drugmaker Akorn has been through a volatile week since it reported better-than-expected quarterly earnings and revenue and raised guidance. Akorn (AKRX) stock initially shot higher on the news, announced before the open Tuesday, but gave back the...
Apple, Lithia Motors Test Key Support Areas
at Investor's Business Daily - Thu Aug 07, 5:02PM CDT
Most stocks will follow the direction of the general market. And now that the market is in a correction, look for leading stocks to pull back and digest gains. One key area to watch for is the 10-week moving average. The line can offer support and...
Market Updates on Pharma Stocks -- Theravance, Akorn, Endo Intl., Pernix Therapeutics, and Depomed
PR Newswire - Thu Aug 07, 8:20AM CDT
On Wednesday, August 6, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 16,443.34, and the S&P 500 closed the day flat at 1,920.24. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, while the index has advanced 5.09% in the previous three months. Investor-Edge has initiated coverage on the following equities: Theravance Inc. (NASDAQ: THRX), Akorn Inc. (NASDAQ: AKRX), Endo International PLC (NASDAQ: ENDP), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), and Depomed Inc. (NASDAQ: DEPO). Free research on these five companies can be accessed at:
Stocks Sag In Rising Trade; Archer Daniels And Avis Rise
at Investor's Business Daily - Tue Aug 05, 9:39AM CDT
Stocks stubbornly held their opening losses Tuesday, despite some strong factory orders and service-sector data. The Nasdaq and S&P 500 dipped 0.5% each. The Dow Jones industrial average slipped 3%. Small caps lagged the pack, with the Russell 2000...
Actavis Guidance Disappoints; Akorn Beats And Raises
at Investor's Business Daily - Tue Aug 05, 9:29AM CDT
Specialty drugmakers and IBD 50 stocks Actavis (ACT) and Akorn were headed in opposite directions in the stock market today after the companies reported their second-quarter earnings and updated their guidance. Actavis' earnings rose 70% over the...